lundi 2 octobre 2017

Onco Actu du 2 octobre 2017

1. Biologie

The Oncogene FOXQ1 Promotes Some Tumor Types but Suppresses Another [Roswell Park]

3. Prévention

Testing a New Option in Ovarian Cancer Prevention [Dana-Farber Cancer Institute]

3.1 Prévention - Tabac

WHO tells governments to reject Philip Morris-funded smoking foundation [Reuters]

4.10 Dép., diag. & prono. - FDA, EMA, NICE,...

FDA’s Gottlieb Preparing To Lower The Bar To Approval [CardioBrief]

4.12 Biopsies liquides

Predicting lung cancer recurrence by analyzing circulating tumor DNA [Stanford Medicine]

4.9 Dép., diag. & prono. - Sein

Women with disabilities may be missing out on cancer screening [Cancer Research UK]

5. Traitements

Q&A with Anil K. Sood, MD, on Ovarian Cancer Research and Treatment [Cancer Research Catalyst]

5.1 Traitements - Pré-clinique

Biologists identify possible new strategy for halting brain tumors [MIT News]

5.12 Immunothérapies

Can T cells be unleashed to attack skin tumors? [UNC]

5.12.6 Immunothérapies - AMM

FDA Approvals for Liver and Stomach Cancer Extend the Reach of Immunotherapy [Cancer Research Catalyst]

5.12.8 Immunothérapies - Economie

The $913M bonanza: Arie Belldegrun and his top team at Kite show you how to make a really rich deal [EndPoints]

5.2 Pharma

Eli Lilly R&D chief Jan Lundberg heads for the exit as CEO assembles a new team at the top [EndPoints]

FDA grants Priority Review for Roche’s Perjeta (pertuzumab) for adjuvant treatment of HER2-positive early breast cancer [Roche]

Roche's Perjeta regimen gets FDA priority review in breast cancer [Reuters]

5.2.2 Pharma - Fusions & Acquisitions

Why would Novartis buy a $2.6B radiotherapy maker? Its neuroendocrine franchise, analyst says [FiercePharma]

Novartis Is Said to Eye Deal for Radioactive-Drug Maker AAA [Bloomberg]

5.2.3 Pharma - économie

Cancer, gene therapy biotechs raise $303M in IPO bonanza [FierceBiotech]

Deciphera IPO Drums Up $128M for Cancer Drug Studies [Xconomy]

5.3 Traitements - FDA, EMA, NICE...

FDA improves access to reports of adverse drug reactions [FDA]

5.3.4 Traitements - AMM (FDA, EMA)

FDA approves Lilly pill for common advanced breast cancer [STAT]

Lilly receives FDA breast cancer pill approval, doubts remain [Pharmafile]

Lilly steps up to rival Pfizer, Novartis with Verzenio breast cancer approval [FiercePharma]

FDA approves new treatment for certain advanced or metastatic breast cancers [FDA]

Gemtuzumab Receives New FDA Approval for Acute Myeloid Leukemia [NCI]

Eli Lilly wins U.S. approval for breast cancer drug [Reuters]

5.4 Traitements - Economie

Ibrutinib for treating relapsed or refractory mantle cell lymphoma [NICE]

NICE knocks-back Janssen's Imbruvica in mantle cell lymphoma [PharmaTimes]

Cheap drug could cut 10% of UK breast cancer deaths, charity says [The Guardian]

5.9.5 IASLC

Loxo Oncology Announces Details of LOXO-292 Abstract to be Presented as Late-Breaking Presentation at the IASLC 18th World Conference on Lung Cancer [Loxo]

Ignyta Announces Updated Data on Entrectinib in ROS1 NSCLC to Be Presented at the IASLC 18th World Conference on Lung Cancer [Ignyta]

6.10 Politiques

Brexit will have large impact on health and NHS, say researchers [Cancer Research UK]

French government proposes big science-spending boost [Nature]

6.10.1 Politiques (USA)

Massachussets Could Shake Up Drug Pricing [Bloomberg]

6.11 Patients

Julia Louis-Dreyfus shares breast cancer diagnosis [The Guardian]

6.13 Soins palliatifs

Many kids dying of cancer get intense care at end of life [Reuters]

6.5 Médecines alternatives

Rigvir strikes back, or: A conversation with a Rigvir flack [Science-Based Medicine]

6.6 Publications

Are preprints the future of biology? A survival guide for scientists [Science]

“No wrongdoing had occurred,” says Karolinska, following investigation of cancer research [Retraction Watch]